Key TakeawaysAstraZeneca announced plans Tuesday for a “new era of growth" with 75% revenue growth and 20 new drug launches by 2030.The pharmaceutical company said it is targeting $80 billion in total annual revenue by 2030, up from $45.8 billion in 2023.AstraZeneca ADRs rose to a record high Tuesday following the announcement. AstraZeneca's (AZN) American depositary receipts (ADRs) rose over 2% to a record high Tuesday after the Anglo-Swedish drug maker announced what it called its “bold ambition” for fut ...

AstraZeneca (AZN) announced its long-term plan to generate $80 billion in total revenues by 2030, which is significantly higher than $43.8 million generated in 2023.By 2030, AstraZeneca plans to launch 20 new medicines, which are also expected to be key contributors to the pipeline. AstraZeneca believes that many of these new medicines will have the potential to generate more than $5 billion in peak-year revenues. AstraZeneca will continue investing in disruptive innovation and transformative new technologi ...

In this articleNOVO.B-DKAZN-GBLLYThe Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021.Costfoto | Future Publishing | Getty ImagesLONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023."We have a lot of confidence in this 80 billion ambition because of the portfolio and the breadth and scale of the portfolio that we see today," AstraZeneca' ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

AstraZeneca (AZN) announced its plans to spend $1.5 billion to build its first manufacturing facility in Singapore. Once built, it will be the company’s first facility to cover the full manufacturing process for its antibody drug conjugates (ADCs) portfolio at a commercial scale.ADCs are next-generation treatments that target cancer cells by delivering highly potent cancer-killing agents through a targeted antibody.AstraZeneca is building the manufacturing site to ensure a safe and reliable supply of ADCs. ...

For Q1 2024, GDP growth in the United States decelerated to 1.6% from 3.4% in the last quarter. There is no doubt that factors like high interest rates and geopolitical tensions have impacted growth. At the same time, inflation has been relatively stubborn, and potential rate cuts will likely be delayed. The markets are, therefore, likely to witness some nervousness. From an investment perspective, it’s a good idea to look at blue-chip stocks to buy with a low beta.I must mention here that rate cuts are ine ...

Johnson & Johnson isn't the ultra-safe stock it used to be.Many healthcare investors look at Johnson & Johnson (JNJ 0.04%) and see a good, safe dividend stock. But I see an investment that's full of uncertainty and risk.The company continually runs into legal problems, and I can't help but wonder if one day it will follow in the path of 3M, which was also once seen as a top investment option for risk-averse investors who just wanted to collect a safe dividend; it, too, has run into many legal problems, and ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside t ...

AstraZeneca has begun the worldwide withdrawal of its COVID vaccine - ending an era in which it saved millions of lives while being dogged by controversy.The jab, developed at Oxford University, was once hailed as "the vaccine for the world" because it could be stored in fridges rather than the ultra-cold freezer temperatures originally required for alternative mRNA shots, making it more suitable for developing countries. But AstraZeneca (AZ) said demand for the jab had tailed off as more up-to-date vaccine ...

In this photo illustration a covid-19 vaccine is seen with the AstraZeneca logo in the background. (Photo Illustration by Nikos Pekiaridis/NurPhoto via Getty Images)Pharmaceutical giant AstraZeneca on Wednesday said it planned to withdraw its Covid-19 vaccine as demand for it has declined. The so-called Vaxzevria vaccine was developed with the University of Oxford and was one of the first shots against Covid-19 to hit the market during the coronavirus pandemic, with millions of people around the world recei ...